Clario Announces Completion of Acquisition of WCG's eCOA Business

The addition of WCG's eCOA capabilities further amplifies Clario's leadership position in providing support for neuroscience drug development, which includes: The addition of WCG's eCOA capabilities further amplifies Clario's leadership position in providing support for neuroscience drug development, which includes: "This acquisition is a game-changer for clinical research in neuroscience," saidTerry Burke, executive vice president and general manager of Clario's eCOA business. "WCG has...

The addition of WCG's eCOA capabilities further amplifies Clario's leadership position in providing support for neuroscience drug development, which includes:

"This acquisition is a game-changer for clinical research in neuroscience," said Terry Burke, executive vice president and general manager of Clario's eCOA business. "WCG has made significant contributions to eCOA in neuroscience trials, and we have long respected their achievements in this space. We've planned a seamless integration with an aim on preserving what's already working well — trials will continue uninterrupted, and the platforms and study teams customers rely on will remain in place. By bringing WCG's eCOA professionals and scientific capabilities to Clario, we can deliver the high-quality data and scientific rigor needed to support new complex studies and to accelerate breakthrough therapies."  

Astorg and Nordic Capital — two leading private equity firms with deep expertise in the healthcare sector — have co-owned Clario since 2019. Novo Holdings and Cinven also support the company as minority shareholders.

Judith Charpentier, co-head of Flagship & head of Healthcare at Astorg, and Daniel Berglund, co-head of Healthcare at Nordic Capital Advisors, commented in a joint statement:
"We are truly excited about Clario's strategic acquisition of WCG's eCOA business, which will further strengthen its position as a global leader in clinical trial endpoint solutions. We are proud to continue our collaboration with Clario's leadership team and support the company's continued growth and innovation journey."

For more information about Clario and its solutions, please visit clario.com.

About Clario
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac solutions and respiratory endpoints.

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012. Clario's shareholders are Astorg, Nordic Capital, Novo Holdings, and Cinven.

For more information, go to Clario.com or follow us on LinkedIn.

Clario Media Contact:
David Malley
[email protected]

Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/clario-announces-completion-of-acquisition-of-wcgs-ecoa-business-302445940.html